临床基因组学市场：按产品/服务、技术、应用、感染疾病、最终用户和地区划分

临床基因组学市场规模预计在 2025 年达到 125 亿美元，预计在 2032 年达到 263 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 11.2%。

全球临床基因组学市场是医疗保健产业中一个快速发展的领域，它从根本上改变了个人化医疗和精准治疗的模式。临床基因组学涵盖对个别基因组成的全面分析，为医疗决策、疾病诊断、治疗选择和预后提供资讯。这个多学科领域弥合了基因组学研究与临床实践之间的差距，使医疗保健提供者能够根据患者独特的基因特征提供量身定制的医疗干预措施。

该市场涵盖广泛的技术、服务和应用，包括全基因组定序、标靶基因组合、药物基因组学检测、肿瘤基因组学和罕见疾病诊断。随着全球医疗保健系统日益采用精准医疗方法，临床基因组学已成为推动药物开发、生物标记发现和治疗优化创新的基础技术。先进定序技术、人工智慧和巨量资料分析的整合显着提高了基因组检测的可及性、准确性和成本效益，使其更易于在全球不同的医疗机构和患者群体中常规临床实施。

市场动态

全球临床基因组学市场受到多种强劲驱动因素的推动，这些因素持续加速其成长轨迹。遗传性疾病、癌症和罕见疾病的全球流行催生了对精准诊断和治疗解决方案的巨大需求，使得临床基因组学成为医疗保健提供者的重要工具。次世代定序(NGS) 技术的进步、基因组检测成本的下降以及数据解读能力的提升，使得基因组分析更加便捷实用，并最终被广泛应用于临床。政府的倡议以及对基因组研究的大量投资，例如国家基因组计划和精准医疗项目，正在为市场扩张提供强劲动力。

医疗专业人员和患者对个人化医疗益处的认识不断提高，再加上全球医疗支出的不断增加，进一步推动了市场成长。然而，市场面临重大製约，包括不同地区法律规范复杂且各不相同，对市场参与企业构成了合规挑战。高昂的初始基础设施成本、熟练的基因组学专业人员短缺以及对资料隐私和安全的担忧对发展构成了重大障碍，尤其是在新兴经济体中。围绕基因检测的伦理考量和潜在的歧视问题也限制了市场应用。由于药物基因组学的应用不断扩大，可以优化药物选择和给药策略，以及人工智慧和机器学习机会的日益融合，以增强数据分析和解释，因此存在巨大的商机。虽然新兴市场提供了尚未开发的成长潜力，照护现场基因组检测和液态切片技术的持续创新为市场扩张和改善患者预后提供了有希望的途径。

本次调查的主要特点

• 本报告对全球临床基因组学市场进行了详细分析，并提供了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），以 2024 年为基准年。
• 它强调了各个领域的潜在商机，并描述了该市场的一系列有吸引力的投资提案。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，概述了全球临床基因组学市场的主要企业。
• 本报告的见解将使负责人和企业经营团队能够就未来的产品发布、最新策略、市场扩张和行销策略做出明智的决策。
• 全球临床基因组学市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过分析全球临床基因组学市场所使用的各种策略矩阵来促进决策。

目录

第一章：调查目标和先决条件

• 调查目的
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要

第三章：市场动态、法规与趋势分析

• 市场动态
• 驱动程式
• 抑制因素
• 机会
• 影响分析
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景
• 产业趋势

4. 2020 年至 2032 年全球临床基因体学市场（按产品和服务划分）

• 介绍
• 设备或系统
• 序列器
• 耗材
• 试剂和套件
• 软体和服务
• 数据分析与解释

5. 全球临床基因体学市场（依技术划分），2020 年至 2032 年

• 介绍
• 下一代定序（NGS）
• 聚合酵素链锁反应（PCR）
• 微阵列
• 桑格定序
• 其他技术（例如 FISH、核型分析）

6. 全球临床基因体学市场（按应用），2020 年至 2032 年

• 介绍
• 肿瘤学
• 癌症诊断和预后
• 感染疾病
• 病原体鑑定和表征（细菌、病毒、真菌、寄生虫）
• 遗传性疾病
• 新生儿筛检
• 心血管疾病
• 遗传性心肌病检测
• 神经系统疾病
• 神经退化性疾病检测（例如阿兹海默症、亨丁顿舞蹈症）
• 其他应用（例如药物基因体学）

7. 2020 年至 2032 年全球临床基因体学市场（依最终使用者划分）

• 介绍
• 医院和诊所
• 诊断实验室
• 製药和生物技术公司
• 其他（学术研究机构等）

8. 全球临床基因体学市场（按地区划分），2020 年至 2032 年

• 介绍
• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 东南亚国协
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 南非
  • 北非
  • 中部非洲

第九章 竞争态势

• Illumina Inc
• Thermo Fisher Scientific Inc
• F Hoffmann-La Roche Ltd
• QIAGEN NV
• Agilent Technologies Inc
• BGI Genomics
• PerkinElmer Inc
• Bio-Rad Laboratories Inc
• Danaher Corporation（Cepheid, IDT）
• Oxford Nanopore Technologies
• Pacific Biosciences
• Myriad Genetics Inc
• Guardant Health
• Eurofins Scientific
• GE HealthCare

第 10 章分析师建议

• 机会
• 一致的机会地图

第 11 章参考文献与调查方法

• 参考
• 调查方法
• 关于出版商

Clinical Genomics Market is estimated to be valued at USD 12.5 Bn in 2025 and is expected to reach USD 26.3 Bn by 2032, growing at a compound annual growth rate (CAGR) of 11.2% from 2025 to 2032.

The Global Clinical Genomics Market represents a rapidly evolving sector within the healthcare industry, fundamentally transforming the landscape of personalized medicine and precision therapeutics. Clinical genomics encompasses the comprehensive analysis of an individual's genetic makeup to inform medical decision-making, disease diagnosis, treatment selection, and prognosis determination. This interdisciplinary field bridges the gap between genomic research and clinical practice, enabling healthcare providers to deliver tailored medical interventions based on patients' unique genetic profiles.

The market encompasses a broad spectrum of technologies, services, and applications including whole genome sequencing, targeted gene panels, pharmacogenomics testing, oncology genomics, and rare disease diagnostics. As healthcare systems worldwide increasingly adopt precision medicine approaches, clinical genomics has emerged as a cornerstone technology driving innovation in drug development, biomarker discovery, and therapeutic optimization. The integration of advanced sequencing technologies, artificial intelligence, and big data analytics has significantly enhanced the accessibility, accuracy, and cost-effectiveness of genomic testing, making it more viable for routine clinical implementation across diverse healthcare settings and patient populations globally.

Market Dynamics

The Global Clinical Genomics Market is propelled by several compelling drivers that continue to accelerate its growth trajectory. The increasing prevalence of genetic disorders, cancer, and rare diseases worldwide has created substantial demand for precise diagnostic and therapeutic solutions, positioning clinical genomics as an indispensable tool for healthcare providers. Technological advancements in next-generation sequencing (NGS), declining costs of genomic testing, and improved data interpretation capabilities have made genomic analysis more accessible and practical for widespread clinical adoption. Government initiatives and substantial investments in genomics research, including national genome projects and precision medicine programs, have provided significant momentum to market expansion.

The growing awareness among healthcare professionals and patients about the benefits of personalized medicine, coupled with increasing healthcare expenditure globally, further drives market growth. However, the market faces notable restraints including complex regulatory frameworks that vary across different regions, creating compliance challenges for market participants. High initial infrastructure costs, shortage of skilled genomics professionals, and concerns regarding data privacy and security pose significant barriers to market penetration, particularly in developing economies. Ethical considerations surrounding genetic testing and potential discrimination issues also limit market adoption. Nevertheless, substantial opportunities exist through expanding applications in pharmacogenomics, which enables optimized drug selection and dosing strategies, and the growing integration of artificial intelligence and machine learning technologies for enhanced data analysis and interpretation. Emerging markets present untapped potential for growth, while continuous innovation in point-of-care genomic testing and liquid biopsy technologies offers promising avenues for market expansion and improved patient outcomes.

Key Features of the Study

• This report provides an in-depth analysis of the global clinical genomics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global clinical genomics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Illumina Inc, Thermo Fisher Scientific Inc, F Hoffmann-La Roche Ltd, QIAGEN NV, Agilent Technologies Inc, BGI Genomics, PerkinElmer Inc, Bio-Rad Laboratories Inc, Danaher Corporation (Cepheid, IDT), Oxford Nanopore Technologies, Pacific Biosciences, Myriad Genetics Inc, Guardant Health, Eurofins Scientific, and GE HealthCare.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global clinical genomics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global clinical genomics market.

Market Segmentation

• Product and Service Insights (Revenue, USD Bn, 2020 - 2032)
  • Instruments or Systems
  • Sequencers
  • PCR Systems
  • Microarray Scanners
  • Automated Liquid Handlers
  • Other Genomic Analyzers
  • Consumables
  • Reagents and Kits
  • Sequencing Chips and Flow Cells
  • Sample Collection Kits
  • Others (Probes and Primers)
  • Software and Services
  • Data Analysis and Interpretation
  • Sequencing Services
  • Others (Clinical Laboratory Services, etc)
• Technology Insights (Revenue, USD Bn, 2020 - 2032)
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Microarray
  • Sanger Sequencing
  • Other Technologies (e.g., FISH, Karyotyping)
• Application Insights (Revenue, USD Bn, 2020 - 2032)
  • Oncology
  • Cancer Diagnosis and Prognosis
  • Therapy Selection and Companion Diagnostics
  • Hereditary Cancer Risk Assessment
  • Minimal Residual Disease (MRD) Monitoring
  • Liquid Biopsy Analysis
  • Infectious Diseases
  • Pathogen Identification and Characterization (Bacterial, Viral, Fungal, Parasitic)
  • Outbreak Surveillance and Strain Typing
  • Antimicrobial Resistance Testing
  • Genetic Disorders
  • Newborn Screening
  • Carrier Screening
  • Prenatal Diagnosis
  • Preimplantation Genetic Testing
  • Diagnosis of Rare and Inherited Diseases
  • Cardiovascular Diseases
  • Inherited Cardiomyopathies Testing
  • Arrhythmia Genetic Testing (e.g., Long QT Syndrome)
  • Aortopathies Genetic Testing (e.g., Marfan Syndrome)
  • Genetic Hypercholesterolemias Testing
  • Neurological Disorders
  • Neurodegenerative Disease Testing (e.g., Alzheimer's, Huntington's)
  • Neuromuscular Disorder Testing (e.g., Duchenne Muscular Dystrophy)
  • Epilepsy Genetic Testing
  • Neurodevelopmental Disorder Testing
  • Other Applications (Pharmacogenomics, etc.)
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Others (Academic and Research Institutes, etc.)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Player Insights
  • Illumina Inc
  • Thermo Fisher Scientific Inc
  • F Hoffmann-La Roche Ltd
  • QIAGEN NV
  • Agilent Technologies Inc
  • BGI Genomics
  • PerkinElmer Inc
  • Bio-Rad Laboratories Inc
  • Danaher Corporation (Cepheid, IDT)
  • Oxford Nanopore Technologies
  • Pacific Biosciences
  • Myriad Genetics Inc
  • Guardant Health
  • Eurofins Scientific
  • GE HealthCare

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Clinical Genomics Market, By Product and Service
  • Global Clinical Genomics Market, By Technology
  • Global Clinical Genomics Market, By Application
  • Global Clinical Genomics Market, By End User
  • Global Clinical Genomics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Clinical Genomics Market, By Product and Service, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Instruments or Systems
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Sequencers
  • PCR Systems
  • Microarray Scanners
  • Automated Liquid Handlers
  • Other Genomic Analyzers
• Consumables
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Reagents and Kits
  • Sequencing Chips and Flow Cells
  • Sample Collection Kits
  • Others (Probes and Primers)
• Software and Services
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Data Analysis and Interpretation
  • Sequencing Services
  • Others (Clinical Laboratory Services, etc.)

5. Global Clinical Genomics Market, By Technology, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Next-Generation Sequencing (NGS)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Polymerase Chain Reaction (PCR)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Microarray
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Sanger Sequencing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Other Technologies (e.g., FISH, Karyotyping)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Clinical Genomics Market, By Application, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cancer Diagnosis and Prognosis
  • Therapy Selection and Companion Diagnostics
  • Hereditary Cancer Risk Assessment
  • Minimal Residual Disease (MRD) Monitoring
  • Liquid Biopsy Analysis
• Infectious Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pathogen Identification and Characterization (Bacterial, Viral, Fungal, Parasitic)
  • Outbreak Surveillance and Strain Typing
  • Antimicrobial Resistance Testing
• Genetic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Newborn Screening
  • Carrier Screening
  • Prenatal Diagnosis
  • Preimplantation Genetic Testing
  • Diagnosis of Rare and Inherited Diseases
• Cardiovascular Diseases
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Inherited Cardiomyopathies Testing
  • Arrhythmia Genetic Testing (e.g., Long QT Syndrome)
  • Aortopathies Genetic Testing (e.g., Marfan Syndrome)
  • Genetic Hypercholesterolemia's Testing
• Neurological Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neurodegenerative Disease Testing (e.g., Alzheimer's, Huntington's)
  • Neuromuscular Disorder Testing (e.g., Duchenne Muscular Dystrophy)
  • Epilepsy Genetic Testing
  • Neurodevelopmental Disorder Testing
• Other Applications (Pharmacogenomics, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Clinical Genomics Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Hospitals and Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Diagnostic Laboratories
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Pharmaceutical and Biotechnology Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (Academic and Research Institutes, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Clinical Genomics Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Product and Service, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Illumina Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Thermo Fisher Scientific Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• F Hoffmann-La Roche Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• QIAGEN NV
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Agilent Technologies Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BGI Genomics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• PerkinElmer Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bio-Rad Laboratories Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Danaher Corporation (Cepheid, IDT)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Oxford Nanopore Technologies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pacific Biosciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Myriad Genetics Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Guardant Health
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eurofins Scientific
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GE HealthCare
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us